Search filters

List of works by Pierre Feugier

Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment

scientific article published on 14 February 2017

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

scientific article published on 25 December 2012

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

scientific article published on 01 April 2020

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

scientific article published on 28 May 2015

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

scientific article published on 29 October 2012

Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study

article

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

scientific article published on 05 October 2018

Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma

scientific article published on 15 March 2019

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

scientific article published in September 2017

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report

scientific article published in March 2017

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

scientific article

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.

scientific article

Paulina is supported by:

About Paulina

Help